IMMX IMMIX BIOPHARMA INC

Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank

Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank

LOS ANGELES, March 10, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (“SVB”) or Silvergate Bank.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio™) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our proprietary SMARxT Tissue-Specific™ Platform produces drug candidates that circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all 3 components of the tumor micro-environment (TME). We believe ImmixBio’s TME Normalization™ technology severs the lifelines between the tumor and its metabolic and structural support. Learn more at

Investor Contact

Suzanne Messere

Stern Investor Relations

Company Contact

  



EN
11/03/2023

Underlying

IMMXIMMIX BIOPHARMA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IMMIX BIOPHARMA INC

 PRESS RELEASE
Free
IMMX IMMIX BIOPHARMA...

Immix Biopharma Announces Other Serious Diseases Strategy

Immix Biopharma Announces Other Serious Diseases Strategy – Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – Company plans to partner-out Other Serious Disease programs – –  On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/refractory AL Amyloidosis – LOS ANGELES, CA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced imp...

August 6, 2025 1 EN
 PRESS RELEASE
Free
IMMX IMMIX BIOPHARMA...

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Poten...

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion – Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – Potential future indication expansion planned – LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious disea...

July 11, 2025 1 EN
 PRESS RELEASE
Free
IMMX IMMIX BIOPHARMA...

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progre...

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis – National Footprint of NEXICART-2 Trial Sites Expanded – –  On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – –  NEXICART-2 interim results were presented at ASCO 2025 – LOS ANGELES, CA, July 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today ann...

July 7, 2025 1 EN
 PRESS RELEASE
Free
IMMX IMMIX BIOPHARMA...

Immix Biopharma Attends FDA CEO Forum in Washington DC

Immix Biopharma Attends FDA CEO Forum in Washington DC – Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. – LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it was selected by FDA, and attended, the FDA CEO forum led by FDA Commissioner Marty A. Makary, M.D., M.P.H. and team at FDA headquarters in Silver Spring, MD, on June 5, 2025....

June 6, 2025 1 EN
 PRESS RELEASE
Free
IMMX IMMIX BIOPHARMA...

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Int...

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint. – NXC-201 met primary endpoint with a complete response (CR) rate of 70% (7/10 patients) – – No relapses recorded to-date; no safety signals identified – – Immix plans Biologics License Application (BLA) for FDA approval – – Results were presented by Heather ...

June 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch